A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors
An Open Label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of IDE574 as Monotherapy in Locally Advanced or Metastatic Solid Tumors and as Combination Therapy With Fulvestrant in Locally Advanced or Metastatic Cancer
IDE574 is a synthetically manufactured small molecule inhibitor that co-targets the lysine acetyltransferase enzymes KAT6 and KAT7.
The purpose of this study is to evaluate the safety, preliminary efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of IDE574 as monotherapy in participants with locally advanced or metastatic solid tumors and as combination therapy with fulvestrant in participants with advanced or metastatic cancer.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Part 1 - Monotherapy Dose Escalation and Expansion:
Part 1A - Monotherapy Dose Escalation Part 1A will evaluate increasing doses of IDE574 to assess safety, tolerability and to determine dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD) or the recommended dose for expansion (RDE) in subjects with advanced or metastatic cancer.
Part 1B - Monotherapy Dose Expansion Part 1B will evaluate in ER+ HER2- advanced or metastatic cancer at one RDE determined from Part 1A or the MTD.
Part 1C - Exploratory Food Effect Sub-study
Part 2 - Combination Dose Escalation and Expansion
Part 2A - IDE574 Combination Therapy with Fulvestrant Dose Escalation Part 2A will evaluate participants with advanced or metastatic cancer with escalating doses of IDE574 in combination with fulvestrant to assess safety, tolerability and to determine DLTs, MTD or RDE.
Part 2B - IDE574 Combination Therapy with Fulvestrant Dose Expansion Part 2B will randomly assign participants with advanced or metastatic cancer to dose levels selected from Part 2A
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: IDEAYA Clinical Trials
- Phone Number: +1-855-433-224
- Email: IDEAYAClinicalTrials@ideayabio.com
Study Locations
-
-
K'alak'i T'bilisi
-
Batumi, K'alak'i T'bilisi, Georgia, 6000
- Recruiting
- High Technology Hospital MedCenter Ltd
-
Principal Investigator:
- Tamta Makharadze, MD
-
Contact:
- Mamuka Sikharulidze
- Phone Number: +995 568 999 559
- Email: sikharulidzemamuka3@gmail.com
-
Tbilisi, K'alak'i T'bilisi, Georgia, 114
- Recruiting
- Pineo Medical Ecosystem
-
Contact:
- Nino Kekenadze
- Phone Number: +995 593 660 940
- Email: Nkekenadze@pineo.ge
-
Principal Investigator:
- Mziuri Zakaraia, MD
-
Tbilisi, K'alak'i T'bilisi, Georgia, 112
- Active, not recruiting
- LLC ARENSIA Exploratory Medicine
-
Tbilisi, K'alak'i T'bilisi, Georgia, 144
- Active, not recruiting
- Geo Hospitals Multiprofile Medical Center Tbilisi
-
Tbilisi, K'alak'i T'bilisi, Georgia, 186
- Active, not recruiting
- LLC Caucasus Medical Centre
-
-
-
-
California
-
Santa Monica, California, United States, 90404-2095
- Active, not recruiting
- UCLA - Parkside Cancer Center
-
-
Connecticut
-
New Haven, Connecticut, United States, 06510-3206
- Recruiting
- Yale School of Medicine - Cedar Street
-
Principal Investigator:
- Patricia LoRusso, MD
-
Contact:
- Karen Seely
- Phone Number: 203-314-3303
- Email: karen.rodriguezvasquez@yale.edu
-
-
Florida
-
Plantation, Florida, United States, 33322
- Recruiting
- Florida Clinical Trials Group
-
Principal Investigator:
- Harshad Amin, MD
-
Contact:
- Sandra Perez
- Phone Number: 772-297-3057
- Email: perezs@floridactg.com
-
-
Georgia
-
Atlanta, Georgia, United States, 30322-1013
- Recruiting
- Winship Cancer Institute, Emory University
-
Principal Investigator:
- Shipra Gandhi, MD
-
Contact:
- Alejandra Bono
- Phone Number: 404-778-0954
- Email: alejandra.maria.bono@emory.edu
-
-
Missouri
-
St Louis, Missouri, United States, 63110-1010
- Recruiting
- Washington University - Siteman Cancer Center
-
Principal Investigator:
- Faisal Fa'ak, MD
-
Contact:
- Pamela Coe
- Phone Number: 314-747-7569
- Email: mpamela@wustl.edu
-
-
New Jersey
-
East Brunswick, New Jersey, United States, 08816
- Recruiting
- START Astera, LLC
-
Principal Investigator:
- Bruno Fang, MD
-
Contact:
- Bruno S Fang
- Phone Number: 732-426-4750
- Email: info@startresearch.com
-
-
New York
-
Lake Success, New York, United States, 11042
- Recruiting
- START New York Long Island, LLC
-
Principal Investigator:
- Geraldine O'Sullivan Coyne, MD
-
Contact:
- Geraldine O'Sullivan Coyne
- Phone Number: 363-207-5160
- Email: g.osullivancoyne@startresearch.com
-
New York, New York, United States, 10032-3729
- Active, not recruiting
- Columbia University Medical Center -161 Fort Washington
-
-
Tennessee
-
Nashville, Tennessee, United States, 37203
- Recruiting
- SCRI Oncology Partners - PPDS
-
Principal Investigator:
- Sarah Premji, MD
-
Contact:
- Connor Frost
- Phone Number: 615-478-3475
- Email: connor.frost@scri.com
-
-
Texas
-
Austin, Texas, United States, 78758
- Recruiting
- NEXT Texas LLC - Austin
-
Principal Investigator:
- Sheena Sahota, MD
-
Contact:
- Heather Watson
- Phone Number: 737-610-5202
- Email: nxtaus_coordinators@nextoncology.com
-
Dallas, Texas, United States, 75039
- Recruiting
- NEXT Texas LLC - Dallas
-
Principal Investigator:
- Faran Polani, MD
-
Contact:
- Carmen Gonzalez
- Phone Number: 210-580-9479
- Email: NXTDFW_Coordinators@nextoncology.com
-
Fort Worth, Texas, United States, 76104
- Recruiting
- START Dallas Fort Worth, LLC
-
Principal Investigator:
- Henry Xiong, MD
-
Contact:
- Henry Xiong
- Phone Number: 682-350-3010
- Email: info@startresearch.com
-
Houston, Texas, United States, 77030-4009
- Recruiting
- MD Anderson Cancer Center
-
Principal Investigator:
- Timothy Yap, MD
-
Contact:
- Desirae Dufner
- Phone Number: 713-524-3434
- Email: DDufner@mdanderson.org
-
Houston, Texas, United States, 77054
- Recruiting
- NEXT Texas LLC - Houston
-
Principal Investigator:
- Jennifer Segar, MD
-
Contact:
- Carmen Gonzalez
- Phone Number: 210-580-9479
- Email: nxthou_coordinators@nextoncology.com
-
San Antonio, Texas, United States, 78229
- Recruiting
- NEXT Texas LLC - San Antonio
-
Principal Investigator:
- David Sommerhalder, MD
-
Contact:
- April Guerra
- Phone Number: 210-580-9500
- Email: NXTSA_Coordinators@nextoncology.com
-
San Antonio, Texas, United States, 78229
- Recruiting
- Start San Antonio, LLC
-
Principal Investigator:
- Amita Patnaik, MD
-
Contact:
- Hector Navarro
- Phone Number: 210-593-5700
- Email: Hector.Navarro@startresearch.com
-
-
Utah
-
West Valley City, Utah, United States, 84119
- Recruiting
- START Mountain Region, LLC
-
Principal Investigator:
- William McKean, MD
-
Contact:
- William B McKean
- Phone Number: 1 (801) 907-4750
- Email: info@startresearch.com
-
-
Virginia
-
Fairfax, Virginia, United States, 22031
- Recruiting
- NEXT Virginia
-
Principal Investigator:
- Mohamad Salkeni, MD
-
Contact:
- Maybelle De La Rosa
- Phone Number: 703-783-4518
- Email: nxtvir_coordinators@nextoncology.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Archival Tissue sample for testing
- Part 1A - Participants with advanced or metastatic cancer who have progressed on/after standard of care therapy or are intolerant to additional effective therapies.
- Female participants with cancer considered to be of childbearing potential (or have tubal ligations only) must be willing to undergo medically induced menopause (Parts 2A and B only)
- Female participants of nonchildbearing potential with cancer must meet at least 1 of the following criteria: Age ≥ 60 years or age <60 years with absence of menstruation for at least 12 months, or had prior removal of both ovaries
- Have Eastern Cooperative Oncology Group performance status (ECOG PS) of ≤1.
- Have adequate bone marrow, renal and liver function.
- Life expectancy of >3 months
- Able to safely administer and retain orally administered study treatment
- Able to comply with contraceptive/barrier requirements
Key Exclusion Criteria:
- Known symptomatic brain metastases or leptomeningeal metastasis
- Known primary CNS malignancy and any other malignancies within 2 years prior to the first dose with the exception of adequately treated localized tumor.
- Have impairment of GI function or GI disease that may significantly alter the absorption of IDE574.
- Have active liver or biliary disease.
- Have active, uncontrolled bacterial, fungal, or viral infection
- Have clinically significant cardiac abnormalities and/or blood clotting events within 6 months before the first dose
- If participants had adverse reactions to previous experimental antitumor treatment that have not recovered to Grade ≤ 1
- Prior irradiation to >25% of the bone marrow.
- Known or suspected hypersensitivity to IDE574/excipients or components (Parts 1 & 2) or fulvestrant/excipients or components (Part 2 only)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Monotherapy Dose Escalation (Part 1A)
Participants with the appropriate tumor types will be treated with escalating doses of IDE574 |
IDE574 |
|
Experimental: Monotherapy Dose Expansion (Part 1B)
Participants with advanced or metastatic cancer will be treated using the RDE or MTD of IDE574 |
IDE574 |
|
Experimental: Combination Dose Escalation (Part 2A) IDE574 + Fulvestrant
Participants with advanced or metastatic cancer will be treated with escalating doses of IDE574 in combination with fulvestrant |
IDE574 Fulvestrant Injection |
|
Experimental: Combination Dose Expansion (Part 2B)
Participants with advanced or metastatic cancer will be randomly assigned to doses of IDE574 + Fulvestrant |
IDE574 Fulvestrant Injection |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Safety and Tolerability of IDE574 in Part 1 A Monotherapy Dose escalation
Time Frame: Following the first dose of IDE574
|
incidence of DLT; incidence and severity of AEs/serious adverse events (SAEs) graded based on CTCAE V6.0 |
Following the first dose of IDE574
|
|
Safety and Tolerability of IDE574 in Part 1B Monotherapy Dose expansion based on incidence and severity of AEs/SAEs
Time Frame: total study duration
|
Incidence and severity of AEs/SAEs graded based on CTCAE V6.0 |
total study duration
|
|
To evaluate anti-tumor activity of IDE574 in Part 1B Monotherapy Dose expansion based on the ORR per RECIST version 1.1
Time Frame: total study duration
|
Objective Response Rate (ORR) per RECIST version 1.1 will be calculated based on the proportion of participants with confirmed Complete Response or Partial Response |
total study duration
|
|
To evaluate anti-tumor activity of IDE574 in Part 1B Monotherapy Dose expansion based on DOR per RECIST version 1.1.
Time Frame: total study duration
|
Duration of response (DOR) per RECIST version 1.1 will be calculated based on the proportion of participants with confirmed Complete Response or Partial Response |
total study duration
|
|
Safety and tolerability of IDE574 in combination with Fulvestrant in Part 2A Combination Dose Escalation based on incidence of DLT
Time Frame: total study duration
|
Incidence of DLT; incidence and severity of AEs/SAEs graded based on CTCAE V6.0 |
total study duration
|
|
Safety and tolerability of IDE574 in combination with Fulvestrant in Part 2B Combination Dose Expansion based on the incidence and severity of AEs/SAEs
Time Frame: total study duration
|
Incidence and severity of AEs/SAEs graded based on CTCAE V6.0 |
total study duration
|
|
Anti-tumor activity of IDE574 in combination with Fulvestrant in Part 2B Combination Dose Expansion based on the ORR per RECIST version 1.1
Time Frame: total study duration
|
Objective Response Rate (ORR) per RECIST version 1.1 will be calculated based on the proportion of participants with confirmed Complete Response or Partial Response |
total study duration
|
|
Anti-tumor activity of IDE574 in combination with Fulvestrant in Part 2B Combination Dose Expansion based on DOR per RECIST version 1.1.
Time Frame: total study duration
|
Duration of response (DOR) per RECIST version 1.1 will be calculated based on the proportion of participants with confirmed Complete Response or Partial Response |
total study duration
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Evaluate the preliminary antitumor activity of IDE574 in Part 1A Monotherapy Dose Escalation based on the ORR per RECIST version 1.1
Time Frame: total study duration
|
total study duration
|
|
Evaluate the preliminary antitumor activity of IDE574 in Part 1A Monotherapy Dose Escalation based on DOR per RECIST version 1.1.
Time Frame: total study duration
|
total study duration
|
|
Evaluate the preliminary antitumor activity of IDE574 in Part 1A Monotherapy Dose Escalation based on Clinical Benefit Rate (CBR)
Time Frame: total study duration
|
total study duration
|
|
Evaluate the preliminary antitumor activity of IDE574 in Part 1A Monotherapy Dose Escalation based on Disease control rate
Time Frame: total study duration
|
total study duration
|
|
Evaluate the pharmacokinetics (PK) of IDE574 in Part 1A Monotherapy Dose Escalation
Time Frame: total study duration
|
total study duration
|
|
Evaluate the PK of IDE574 in Part 1B Monotherapy Dose Expansion
Time Frame: total study duration
|
total study duration
|
|
Evaluate antitumor activity of IDE574 in Part 1B Monotherapy Dose Expansion
Time Frame: total study duration
|
total study duration
|
|
Evaluate antitumor activity of IDE574 in Part 1B Monotherapy Dose Expansion based on DCR for other solid tumor types
Time Frame: total study duration
|
total study duration
|
|
Evaluate the preliminary antitumor activity of IDE574 in combination with Fulvestrant Part 2A Combination Dose Escalation based on ORR per RECIST version 1.1
Time Frame: total study duration
|
total study duration
|
|
Evaluate the preliminary antitumor activity of IDE574 in combination with Fulvestrant Part 2A Combination Dose Escalation based on DOR per RECIST version 1.1
Time Frame: total study duration
|
total study duration
|
|
Evaluate the preliminary antitumor activity of IDE574 in combination with Fulvestrant Part 2A Combination Dose Escalation based on CBR per RECIST version 1.1
Time Frame: total study duration
|
total study duration
|
|
Evaluate the PK of IDE574 in Part 2A Combination Dose Escalation
Time Frame: total study duration
|
total study duration
|
|
Evaluate antitumor activity of IDE574 in combination with Fulvestrant in Part 2B Combination Dose Expansion based on CBR per RECIST version 1.1
Time Frame: total study duration
|
total study duration
|
|
Evaluate the PK of IDE574 in Part 2B Combination Dose Expansion
Time Frame: total study duration
|
total study duration
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- IDE574-001
- 178299 (Other Identifier: Regulatory Agency Identifier Number (s))
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.